MedTrace Logo

Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome

NCT00272311 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2019-02-27

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.

Conditions

Interventions

DRUG

Aspirin

Dosage

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Florida Atlantic University

    lead OTHER

Principal Investigators

  • Charles H Hennekens, MD, DrPH · Florida Atlantic University

  • Wendy R Schneider, MSN, CCRC · Florida Atlantic University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272311 on ClinicalTrials.gov